CTLA4 and non-small cell lung carcinoma: A very recent study from Schoenfeld et al. [45] found that combined PD-L1 and CTLA-4 inhibition in NSCLC resistant to PD-L1 inhibition was relatively well tolerated, with an overall prevalence of grade 3 or higher treatment-related AEs compared with the 22% prevalence detected with durvalumab–tremelimumab in the ARCTIC trial [27].